欢迎访问《现代生物医学进展》编辑部！

目的：分析尤瑞克林联合依达拉奉治疗房颤合并脑栓塞的疗效以及对神经功能的影响。方法：选取我院2013 年1 月至2015 年1 月收治的房颤合并脑栓塞患者220 例，随机分为实验组与对照组，每组各110 例。实验组患者采用尤瑞克林联合依达拉奉药物治疗，对照组采用低分子肝素治疗，记录治疗前后两组患者的凝血功能，对比两组患者的临床疗效，采用美国国立卫生研究院卒中量表(NIHSS)评价患者神经功能受损程度，日常生活活动能力量表（Barthel 指数）评价患者的神经功能恢复情况。结果：治疗后两组患者的NIHSS 评分较治疗前降低，且实验组明显低于对照组，Barthel 指数较治疗前升高，且实验组明显高于对照组，差异均有统计学意义（P<0.05）；治疗后两组患者凝血酶时间（TT）、活化部分凝血活酶时间（APTT）、凝血酶原时间（PT）、INR均显著高于治疗前，且实验组显著高于对照组，差异具有统计学意义（P<0.05）；治疗后实验组患者的总有效率为90.91%，显著高于对照组的60.09%，差异有统计学意义（P<0.05）。结论：尤瑞克林联合依达拉奉治疗房颤合并脑栓塞疗效较好，可修复受损的神经系统，值得在临床上大力推广。

英文摘要:

Objective:To analyze the effect of urinarykallid combined with edaravone in the treatment of atrial fibrillation with cerebral embolism and the its impact on nerve function.Methods:Selected 220 cases of patients with atrial fibrillation with cerebral embolism who were treated in our hospital from January 2013 to January 2015, and were randomly divided into experimental group and control group, with 110 cases of patients in each group. The patients in the experimental group were treated with urinarykallid combined with edaravone, and the control group were treated with low molecular heparin,recorded the coagulation function of patients in two groups before and after treatment, compared the clinical efficacy of patients in two groups, evaluated the degree of neurological impairment by the national institutes of health stroke scale (NIHSS), evaluated the recovery of neurological function of patients by the activity of daily living scale (Barthel index).Results:The NIHSS scores of patients in the two groups after treatment were lower than before treatment, and the experimental group was significantly lower than that of the control group, the Barthel indexes were higher than before treatment, and the experimental group was significantly higher than that of the control group, the differences were statistically significant(P<0.05); The thrombin time(TT), activated partial thromboplastin time(APTT), prothrombin time(PT) and INR of patients in the two groups after treatment were significantly higher than before treatment, and the experimental group was significantly higher than the control group, the differences were statistically significant (P<0.05); The total effective rate of the experimental group was 90.91%, which was significantly higher than 60.09% of the control group, the difference was statistically significant (P<0.05).Conclusion:The effect of urinarykallid combined with edaravone in the treatment of atrial fibrillation with cerebral embolism is better, is able to repair the damaged nervous system, which is worthwhile to be popularized in clinic.

View Full Text View/Add Comment Download reader